(Q38372055)

2 September 2017

1 reference

title

Labetalol: a review of its pharmacology and therapeutic use in hypertension (English)

1 reference

2 September 2017

main subject

arterial hypertension

0 references

1

Brogden RN

1 reference

2 September 2017

Heel RC

2

1 reference

2 September 2017

Speight TM

series ordinal

3

1 reference

2 September 2017

Avery GS

series ordinal

4

1 reference

2 September 2017

publication date

1 April 1978

1 reference

2 September 2017

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

251-270

1 reference

Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects

2 September 2017

cites work

1 reference

12 December 2020

Metabolism of labetalol by animals and man.

1 reference

12 December 2020

Scalp tingling in patients on labetalol

1 reference

12 December 2020

Controlled comparison of labetalol and propranolol in the management of severe hypertension

1 reference

12 December 2020

Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension

1 reference

12 December 2020

Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol

1 reference

12 December 2020

A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug

1 reference

12 December 2020

Scalp tingling and difficulty in micturition in patients on labetalol

1 reference

12 December 2020

Proceedings: The effects of AH 5158 on the overflow of transmitter and the uptake of (3H)-(--)-noradrenaline in the cat spleen

1 reference

12 December 2020

Pressor response after intravenous labetalol

1 reference

12 December 2020

Labetalol in long-term treatment of hypertension

1 reference

12 December 2020

Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients

1 reference

12 December 2020

Haemodynamic effects of long-term oral labetalol

1 reference

12 December 2020

Pharmacological basis for antihypertensive effects of intravenous labetalol

1 reference

12 December 2020

Rate of onset of hypotensive response with oral labetalol [proceedings]

1 reference

12 December 2020

Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine

1 reference

12 December 2020

Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma

1 reference

12 December 2020

Labetalol in resistant hypertension

1 reference

12 December 2020

Pharmacokinetic and pharmacological studies with tolamolol in man

1 reference

12 December 2020

Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension

1 reference

12 December 2020

Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol

1 reference

12 December 2020

The metabolism of labetalol in animals and man

1 reference

12 December 2020

Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise

1 reference

12 December 2020

Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent

1 reference

12 December 2020

Experience with labetalol in hypertension.

1 reference

12 December 2020

The anti-hypertensive efficacy of combined alpha- and beta-adrenoreceptor blockade with phentolamine-oxprenolol or with labetalol (AH 5158)

1 reference

12 December 2020

Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol

1 reference

12 December 2020

Double-blind trial of labetalol

1 reference

12 December 2020

Labetalol in hypertensive emergencies

1 reference

12 December 2020

Some complementary data on AH 5158, an inhibitor of both alpha-and beta-adrenoceptors [proceedings]

1 reference

12 December 2020

Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs

1 reference

12 December 2020

Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise

1 reference

12 December 2020

Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension

1 reference

12 December 2020

The effects of a new alpha- and beta-adrenoceptor antagonist (AH5158) upon the general and coronary haemodynamics of intact dogs

1 reference

12 December 2020

Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol

1 reference

12 December 2020

The effects of oral AH 5158, a combined α and β-adrenoceptor antagonist, in healthy volunteers

1 reference

12 December 2020

Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study

1 reference

12 December 2020

Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]

1 reference

12 December 2020

Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals

1 reference

12 December 2020

Affinity of labetalol for ocular melanin.

1 reference

12 December 2020

Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

1 reference

12 December 2020

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects

1 reference

12 December 2020

Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise

1 reference

12 December 2020

Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent

1 reference

12 December 2020

Cardiovascular effects of labetalol during halothane anaesthesia

1 reference

12 December 2020

Anti-hypertensive action, time of onset and effects on carbohydrate metabolism of labetalol

1 reference

12 December 2020

Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension

1 reference

12 December 2020

Relationship between plasma concentrations and pharmacological effects of labetalol

1 reference

12 December 2020

Modification of pressor responses induced by 'cold' [proceedings]

1 reference

12 December 2020

Labetalol (AH5158), a Competitive Alpha-and Beta-Receptor Blocking Drug, in the Management of Hypertension

1 reference

12 December 2020

Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses

1 reference

12 December 2020

The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen

1 reference

12 December 2020

Labetalol in hypertension

1 reference

12 December 2020

A study of labetalol in patients of European, West Indian and West African origin

1 reference

12 December 2020

Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors

1 reference

12 December 2020

Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo

1 reference

12 December 2020

10.2165/00003495-197815040-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1010182380

0 references

1 reference